Abecma
What Abecma is used for
Abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti CD38 antibody and have demonstrated disease progression on the last therapy.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Advanced therapy: a gene, cell or tissue-engineered medicine.
- PRIME: a priority medicine that the EMA supported early because it may meet an unmet need.
Key facts
- Brand
- Abecma
- Active substance
- idecabtagene vicleucel
- Disease area
- Multiple Myeloma
- Medicine group
- Antineoplastic agents
- ATC code
- L01
- Marketing authorisation holder
- Bristol-Myers Squibb Pharma EEIG
- Authorised in the EU since
- 2021
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Abecma used for?
Abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti CD38 antibody and have demonstrated disease progression on the last therapy.
What is the active substance in Abecma?
Abecma contains idecabtagene vicleucel.
Who makes Abecma?
The EU marketing authorisation holder is Bristol-Myers Squibb Pharma EEIG.
Is Abecma an orphan medicine?
Yes. Abecma is designated an orphan medicine in the EU, for a rare disease (Multiple Myeloma).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU